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Abstract
Breast cancer (BC) remains the leading cause of death in women worldwide, despite the 
improvements of cancer screening and treatment methods. Recently, development of novel 
anticancer drugs for the improved prevention and treatment of BC is in the center of research. 
The anticancer effects of bromelain, as enzyme extract derived from the pineapples, contains 
chemicals that interfere with the growth of tumor cells. The aim of this study was to evaluate 
the effect of radiosensitizing of bromelain in 4T1 BC cells. This investigation utilized the 
3-(4,5-dimethylthiazol-2-yl)-2,5-dimethyltetrazolium bromide assay to characterize the cytotoxicity 
of bromelain. Colony formation method was used to establish the truth of the capability of bromelain 
to make sensitive to radiation therapy. Flowcytometry performed to define the contribution the 
apoptosis effect to bromelain mediated radiosensitization of 4T1 cells. Bromelain reduced growth 
and proliferation of 4T1 cell as a concentration-dependence manner significantly. The survival of 
4T1 cancer cells was decreased after combined treatment in a number and size-dependent manner 
with regard to the control group (P < 0.05). Combination of bromelain with radiation does not 
influence 4T1 cell apoptosis. The results suggested that bromelain can inhibit the growth and 
proliferation and reduce survival of 4T1 BC cells and might be used as a candidate radiosensitizer 
in BC patient.
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Introduction
Breast cancer (BC) is one of the most 
common cancers and the original reason of 
cancer-related death in women worldwide. 
Clinically conventional treatment has been 
adopted for BC treatment mainly including 
chemotherapy, surgery, radiotherapy (RT), 
and some combined treatment strategies.[1-5] 
Chemotherapy is used for systemic control, 
whereas surgery and RT are used to the 
management of cancer. RT is commonly 
recommended as primary or adjuvant 
treatment modality for BC with the benefit 
rate as high as 80%–90%. Despite its 
critical role in cancer treatment, there are 
challenges related to RT. The maximum 
dose of irradiation which can be delivered 
to tumors and its curative effect are often 
limited by the similarities in the energy 
absorption attributes of the malignant 
tissues and normal ones and resulting in 
radiation toxicity to the nearby healthy 
tissues. In addition, the majority of cancer 
types contain a high degree of heterogeneity 
in microenvironment, phenotype, genotype, 
many hypoxic cells, and huge amount of 
enzymes should be protected cells to RT 
and variability in radiation sensitivity.[1-4] To 
address these challenges, tumor-selective 
radiosensitizers which can increase the 
selectivity of ionizing radiation (IR) to 
cancer cell without hampering the activities 
of healthy cells are extremely desired 
and have been widely investigated. The 
use of radiosensitizers combined with 
low-linear energy transfer radiations can 
increase normal tissue radioresistance, 
therapeutic efficacy by allowing to decrease 
the essential treatment irradiation dose, 
and resulting in minimizing the risk of 
recurrence. As is well defined there are 
four factors that influence radio-resistance 
i) repair of DNA, ii) reoxygenation, iii) 
redistribution of the cell cycle and iv) 
repopulation (the”4 R's”). Therefore, 
any pharmacological agents purposed at 
sensitizing cells to RT would require to 
target one or more of these factors. Whereas 
many agents have been discovered based 
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on this rule, the adverse effects of the agent itself often ban 
its gaining application as a radiosensizer. Thus, discovery 
of modern radiosesitizers with low unwanted effects 
has become a region of interest for medical oncology 
researchers. Recently, the attractive in plant-taken natural 
materials for BC therapy and supportive care of cancer has 
enhanced.[1,6-9]
Bromelain is one of the cysteine protease found in the 
pineapple plant. Bromelain has been chemically identified 
since 1875 and is consumed as a phytomedical compound. It 
can be used to prevent diabetes and various cardiovascular 
diseases. A wide range of studies has been suggested that 
bromelain is useful for blood coagulation-related diseases, 
enhanced absorption of drugs, particularly of antibiotics, 
inflammatory, reversible inhibition of platelet aggregation, 
surgical traumas, and many intestinal and cancers. Since 
bromelain could increase the expression of p53 and Bax 
genes, decrease the activity of cell survival regulators such 
as Akt and Erk and also inhibit NF-κB, Cox-2, and PGE2 
activity.[10,11] According to the best of authors’ knowledge, 
there is no any report document on the functions of 
bromelain as a radioresistant, and this work is the first to 
investigate its radiosensitizing effects. The purpose of the 
present study was to determine the ability of bromelain to 
sensitize mouse 4T1 BC cells to irradiation.
Materials and Methods
Cell culture
4T1 (mouse BC) and L929 (mouse fibroblast) cell lines 
were obtained from the Pasteur Institute (Tehran, Iran). 
Cells were maintained in Roswell Park Memorial Institute 
medium 1640 (Gibco Invitrogen) containing 10% fetal 
bovine serum (Gibco-Invitrogen), 2 g/l sodium bicarbonate, 
and 1% penicillin/streptomycin (Gibco-Invitrogen). 
Cells were grown in a humidified incubator at 37°C, at 
a 95% air −5% CO
2
 atmosphere. When the cells reached 
80% confluences and subcultured, they were harvested 
with 0.5 g/l trypsin (Gibco Laboratories) and 0.2 g/l 
ethylenediaminetetraacetic acid (Gibco Laboratories) for 
4 min for further passages. In all experiments, cells were 
seeded and then incubated 24 h before each assay.
Drug preparation
Bromelain was obtained from Merck (Darmstadt, Germany) 
and the stock solution was made at concentrations of 
1000 µg/ml. Stock solution was filtered the final treating 
concentrations were obtained using diluting in a suitable 
culture medium.
3-(4,5-dimethylthiazol-2-yl)-2,5-dimethyltetrazolium 
bromide assay
Cell viability was defined by 3-(4,5-dimethylthiazol-
2-yl)-2,5-dimethyltetrazolium bromide (MTT) assay. 
Almost 5000 cells/well were plated in 96-well culture 
dish to determine the effect of bromelain on proliferation 
4T1 cells. After 24 h incubation, the cells were treated with 
different concentrations of bromelain, that is, 0, 5, 10, 20, 
40, 50, 75, 100, 200, 300, 400, and 600 µg/ml for 24.[12] 
After the treatment period, 20 µl of MTT of 5 mg/ml in 
PBS were added to each well and left for 3–4 h at 37°C 
within the incubator. Following the incubation, MTT 
solution was eliminated and 100 µl of dimethyl sulfoxide 
added for 20 min at 37°C. Absorbance was measured 
using a multidetection microplate reader at the working 
wavelength of 540 nm. Experiments were repeated at least 
three times on different days.
Cellular-growth curve
To measure doubling time and cellular-growth curves, 
cells were plated in a 12-well plate with a concentration 
of 5–6 × 104 per well in triplicate. The culture media of 
each plate were changed every 3 days through the 6 days. 
Cell numbers were defined every 24 h by counting cells 
under microscope after trypsinization using trypan blue. 
To calculate the Doubling time (TD), growth curve was 
plotted on the common log scale and TD was measured by 
using the equation:
TD duration log2
log finalconcentration / initialconcentr
= ×( ) /
( ( ation))
Cell irradiation
Cells were irradiated by 6 MV X-ray photon using a clinical 
accelerator (Primus, Siemens Ltd., Germany), located in the 
Parsian hospital, Shahrekord, Iran, at doses of 0–6 Gy with a 
dose rate of 200 cGy min-1. Control groups were placed under 
the 6 MV photon beam for the same period of time as well. 
However, the controls did not receive any radiation over this 
procedure since the source shutter has already been closed. 
Irradiations were performed with a source-surface distance 
of 100 cm and a field size of 20 cm × 20 cm. A schematic 
of Plexiglas (polymethyl methacrylate [PMMA]) phantom 
which fabricated for this study is shown in Figure 1. Two 
centimeters of a Plexiglas (PMMA) sheet (water equivalent) 
was placed on the top of the plate to serve as a build-up 
Figure 1: In vitro radiation experiment setup[24]
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material [Figure 1]. Experiments were repeated at least three 
times on different days.
Clonogenic survival assay
Cells were seeded in 6-well microplates in triplicate different 
cell numbers were for different doses of irradiation (100, 200, 
600, and 1000 cells were for 0, 2, 4, and 6 Gy, respectively). 
After overnight, cells were treated with bromelain in 
concentration IC
50
 (µg/ml) for 24 h. At the end of the treatment 
period, cells were irradiated by 6 MV X-ray photon at doses 
of 0–6 Gy. After irradiation, cells were incubated at 37 °C in 
a humid 5% CO
2
 atmosphere. Culture medium per dish was 
changed every 2 days. After 7 days, Colonies comprising 
50 cells were stained with 0.5% crystal violet in 70% ethanol 
and counted by Image J software version 1.47 (National 
Institutes of Mental Health, Bethesda, Maryland, USA). 
Plating efficacy (PE) and survival fraction (SF) was calculated 
mathematically using the following equations:
PE number of colonies / number of seeded cells=
SF number of colonies / number of seeded cells PE= ×( ) .
Flowcytometry analysis
Flowcytometry analysis was used to define the contribution 
the apoptosis effect to bromelain-mediated radiosensitization 
of 4T1 cells. In brief, 300 × 103 cells were plated onto 
coverslips in 6-well plates and treated with bromelain in 
concentration IC
50
 (µg/ml) for 24 h. Following the period 
of time, cells were irradiated at doses of 0–6 Gy by 6 
MV X-ray photons and after 8 h, flowcytometry analysis 
was performed using a BD LSR II Flow cytometer (BD 
Biosciences, Heidelberg, Germany). Flowcytometry data 
were analyzed using Flow Jo software 7.6.1 software (Tree 
Star, Ashland, OR, USA). Externalized phosphatidylserine 
was detected by Annexin V-fluorescein isothiocyanate 
(FITC)/propidium iodide staining (BD Biosciences). 
Annexin V-FITC-positive/propidium iodide-negative cells 
were assumed early apoptosis and double-positive cells were 
assumed late apoptotic/secondary necrotic. Experiments 
were repeated at least three times on different days.
Statistical analyses
All the experiments were repeated three times. All the data 
were analyzed by one-way ANOVA test using GraphPad in 
Stat (Graph Pad Prism 6, San Diego, CA, USA). Data are 
presented as mean ± standard deviation and P < 0.05 were 
deemed to be statistically significant.
Results
Bromelain-induced inhibition of proliferation
The result from the previous study was used to obtain the 
inhibition of 4T1 cells viability by 50% (IC
50
 value).[12] The 
values of IC50 (µg/ml) was obtained for 4T1 cells, 95 after 
24 h of incubation with bromelain.
Cellular-growth curve
Cellular-growth curves were calculated for 4T1 cells as 
previously explained manner in materials and methods 
section. TD values of 19.77 h at 4T1 BC cells was 
determined.
Enhancement of radiation-induced clonogenic cell kill
To determine the radiosensitivity effects of bromelain at 
IC
50
 (µg/ml) and various IR doses of 4T1 cells, clonogenic 
assays were performed. As presented in Figure 2a-h, 
24 h before administration of bromelain at an IC
50
 of 
95 (µg/ml) with X-radiation enhanced the kill of 4T1 
colognes achieved by either treatment alone.
The IC
50
 value obtained following the exposure of 4T1 cells to 
X-rays alone or in the presence of 95 (µg/ml) bromelain were 
1.92 ± 0.14 and 1.25 ± 0.05 Gy, respectively. The sensitivity 
of 4T1 cells to radiation was increased after incubation 
with an IC
50
 of 95 (µg/ml) of bromelain after an incubation 
period of 24 h. Percentage of plating efficiency was found 
to be 52.13 after pretreatment [Figure 2a]. The SFs of the 
cells were 72.9% [Figure 2c and i], 25.6% [Figure 2e and i], 
and 3.8% [Figure 2g and i] for 2, 4, and 6 Gy alone and 
50.7% [Figure 2d and i], 17.4% [Figure 2f and i], and 2.7% 
[Figure 2h and i] for 2, 4, and 6 Gy in the presence of 
bromelain, respectively. The sensitivity of 4T1 cells to 
radiation was increased by 95 µg/ml bromelain for all 
X-rays doses (P < 0.05) [Figure 2]. These results show the 
radiosensitizing activity of bromelain.
Flowcytometry combination of bromelain with radiation 
does not influence 4T1 cell apoptosis
To define the contribution, the apoptosis effect to 
bromelain-mediated radiosensitization of 4T1 cells, 
Annexin V staining was determined in cells 8 h after 
RT. Gates were positioned according to nonstained cells 
and negative controls. As shown in Figure 3a, b, and i, 
bromelain significantly induces 26.14% apoptosis and 
18.62% necrosis, 24 h treatment, compared with 14.22% 
and 0.5% of the control cells, respectively. However, we 
did not observe any enhancement in other groups – induced 
apoptosis treated either with RT alone or in combination 
with bromelain [Figure 3]. Furthermore, Figure 3 indicated 
an increase in late apoptotic event of individual and 
combination therapies compared with the control cells. We 
found a significant reduction in lately apoptotic event for 
bromelain + RT treatment; 11.34 and 10.54 compared with 
RT 19.64% and 43.04% in 4 Gy [Figure 3e, f, and i] and 
6 Gy alone, respectively [Figure 3g, h, and i].
Discussion
Bromelain was took out from natural pineapple which 
was known as an antioxidant in various in vitro study 
models. Bromelain has been reported to promote apoptosis, 
particularly in BC cells. This component also has potent 
anti-inflammatory effects and has been the focus of 
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research involving inflammatory conditions. Clinical trials 
indicate that it is effective in reducing acute sinusitis[13] and 
osteoarthritis of the knee.[14] Bromelain also has the ability 
to control edema[15] and support fibrinolysis; in addition, 
it has been studied for its debriding effects on burn 
wounds.[16] Bromelain’s mechanisms of action reduction of 
secretion of pro-inflammatory chemokines and cytokines.[17]
Numerous studies have shown that bromelain has 
immunomodulatory and antitumor properties.[18,19] In a 
study, Dhandayuthapani et al.[20] reported the influence 
of bromelain in inducing cell death by activation of the 
apoptosis mechanisms in GI-101A cells. They observed 
that with increasing the concentrations of bromelain into 
the mentioned cells, the apoptosis-related cell death in BC 
cells could be also increased.
Bromelain has varied biologic effects. To date, numerous 
studies have investigated the anticancer effect of bromelain. 
Their findings showed that bromelain made the cytotoxic 
effects on human prostate cancer cell (PC3), human 
gastric cancer cell (AGS)[21] human skin fibroblast 1184, 
human BC (MDA-MB-468 and MDA-MB-231)[22] and 
mouse BC (4T1),[12] murine lung carcinoma, melanoma, 
lymphoma cells[23,24] epidermoid carcinoma, melanoma,[23] 
and malignant peritoneal mesothelioma.[25] From the 
results obtained in our study, bromelain in the time of 
incubation 24 h reduced growth and proliferation of 4T1 
cell as a concentration-dependent manner significantly. This 
finding in 24 h of incubation is agreeing with their results. 
Mechanism of action of bromelain can be related to the 
enhancement in the activity of caspase-3 and caspase-9 
that play a vital role in apoptotic cell death induced by 
bromelain.[20]
Results of clonogenic formation assay showed the survival 
of 4T1 cells was decreased after combined treatment in a 
number and the size-dependent manner with respect to the 
control group significantly (P < 0.05).
As it is shown in Figure 3, bromelain significantly induces 
26.14% apoptosis and 18.62% necrosis, 24 h treatment, 
compared with 14.22% and 0.5% of the control cells, 
respectively. However, there was no significant enhancement 
in induced apoptosis treated either with RT alone or in 
radiation combination with bromelain in other groups.
Figure 2: Bromelain sensitizes 4T1 cells to irradiation. Bromelain was administered 24 h before X-rays and 7 days later clonogenic assay was carried out. 
Control group cells (a). Cells were treated with Bromelain (b). 2 Gy (c). Bromelain + 2 Gy (d), 4 Gy (e). Bromelain + 4 Gy (f). 6 Gy (g). Bromelain + 6 Gy (h). 
The survival curves derived from the clonogenic assay experiments treated with or without bromelain were significantly different (P < 0.05) (i). The 
experiments were performed in triplicate and data are presented as mean ± standard deviation of three separate experiments
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Clonogenic formation assay was used to evaluate potential 
radiosensitizer compounds in several studies. They have 
indicated a significant reduction in number, size colonies, 
and survival that received combination treatment with respect 
to the radiation therapy alone group. They find the effect of 
other different agents as radiosensitizer on differentiated cells, 
such as olaparib, rucaparib, elesclomol, and 17-DMAG on 
human PC3 cell lines, PC3 and LNCaP, Huaier on human BC 
cell lines; MCF-7 and MDA-MB-231.[1,26] Futhermore, many 
researchers worked on many cells, including LY2603618, 
MK87776, and AZD1775 on human papillomavirus(+) 
human head-and-neck squamous cell carcinoma (HNSCC) 
cells; UD-SCC-2, UM-SCC-47, and UPCI-SCC-154, EhB4 
on HNSCC cells; Cal27, MSK-921, and Fadu, Human polo-
like kinase 1 (PLK1) on human esophageal squamous cell 
carcinoma cells; KYSE 70, and KYSE 150, ganetespib on 
human Hepatocellular carcinoma  cells; Hep3b, HepG2 and 
HUH, AZD6738 and ATM inhibitor KU-55933 on different 
cell lines; CAL27, FaDu, A549, PJ34, PJ41, T24, A2780, 
RT4, NCI-H1838, NCI-H1373, and DU-4475, MZ-6 and 
MZ-14 on human hepatocellular liver carcinoma cell line 
HepG2.[3,8,27-31] Outcomes of this study are in good agreement 
with their results.
On the other hand, findings of flow cytometry indicated 
a significant reduction in apoptotic events. It can be 
Figure 3: The effect of bromelain on apoptosis in 4T1 cells. The cells have been treated with bromelain and/or radiation, harvested 8 h after treatment, stained 
with Annexin V/PI and analyzed by flow cytometric analysis. Control group cells (a). Cells were treated with bromelain (b). 2 Gy (c). Bromelain + 2 Gy (d), 
4 Gy (e). Bromelain + 4 Gy (f). 6 Gy (g). Bromelain + 6 Gy (h). The bar graph shows the percentage of all apoptotic events following bromelain and/or 
radiation treatment (i). The data are presented as mean ± standard deviation of at least three independent experiments
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conducted that bromelain inhibits the effect of radiation 
on cancer cells. Our results of flow cytometry are not 
in line with the findings in the colony formation assay. 
In various reports have shown that radiation-induced 
apoptosis is enhanced by some agents such as apigenin, 
curcumin, genistein, sulforaphane, benzyl isothiocyanate, 
olaparib, rucaparib, elesclomol, 17-DMA, LY2603618, 
MK87776, and AZD1775, EphB4, human PLK1.[23,27,29,32,33] 
Our observations are opposite of their results. However, in 
many studies such as Rafehi et al.,[34] clonogenic formation 
assay was introduced as the gold standard to investigate 
radiosensitizers.
Conclusion
In summary, our results showed that bromelain could 
inhibit the growth and proliferation of mouse BC 4T1 cell 
line. It can reduce the survival of these cells. According to 
the gold standard clonogenic formation assay, bromelain 
can be a candidate radiosensitizer. While clinical relevant 
studies are needed to achieve the toxicity and the efficacy 
of bromelain, these findings recommend that it is necessary 
to further investigation as a potential radiosensitizer for 
BC. Further researches in vitro and in vivo of the effect 
of the radiosensitizing agents in combination with RT may 
advance progress of this treatment strategy for the clinical 
management of BC.
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